Management of Premenstrual Dysphoric Disorder: A Scoping Review

Carlini, Sara V.; Scalea, Teresa Lanza di; McNally, Stephanie Trentacoste; Lester, Janice; Deligiannidis, Kristina M.

doi:10.2147/ijwh.s297062

Cited by 22 publications

(9 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EFGT was found to improve self-compassion and sexual function and reduce the components of pain perception and couple burnout ( 106 ). There are a variety of alternative and complementary medicine treatments under evaluation such as nutraceuticals, acupuncture, and yoga, Vitex agnus-castus ( 107 ) , Hypericum perforatum ( 108 , 109 ), Crocus sativus ( 110 ), Elsholtzia splendens , and Ginkgo biloba ( 111 , 112 ). Neuromodulation techniques can be explored to strengthen the connectivity between prefrontal control and limbic structures to improve the symptoms and prevent future episodes.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic validity of premenstrual dysphoric disorder: revisited

Naik,

Nidhi,

Kumar

et al. 2023

Front. Glob. Womens Health

View full text Add to dashboard Cite

The World Health Organization (WHO) and American Psychiatric Association (APA) have recognised premenstrual dysphoric disorder (PMDD) as an independent diagnostic entity, legitimising the distress and socio-occupational impairment experienced by affected women. However, the biological validity of this diagnosis remains inexplicit. This illness has also been criticised for a feminist-led, sympathetic reaction to the modern cultural challenges of urban, literate, employed, high-functioning women. This article systematically reviews existing literature on PMDD using the criteria established by Robins and Guze for the validity of a psychiatric diagnosis (clinical description, laboratory study, exclusion of other disorders, follow-up study, and family study). Despite the early recognition of premenstrual syndrome (PMS) in the 1950s, the research has encountered challenges due to two groups of proponents viewing it with psychologising bias and medicalising bias. PMDD is currently understood as the most severe form of PMS, characterised by the presence of psychological features. Recent evidence suggests that PMDD perhaps has neurodevelopmental underpinnings (attention deficit hyperactive disorder, adverse childhood experiences) affecting the fronto-limbic circuit that regulates the emotions. In addition, the affected individuals exhibit an increased sensitivity to gonadal hormonal fluctuations as observed during premenstrual, pregnancy, and perimenopausal phases of life. The prevalence is comparable between high-income countries and low- and middle-income countries (LAMIC), refuting the notion that it mostly affects modern women. Instead, a greater prevalence is observed in LAMIC. Despite the fact that educated women possess knowledge regarding the importance of getting help, there is a prevalent issue of inadequate help-seeking behaviour. This can be attributed to the perception of seeking help as an isolating experience, which is influenced by profound internalised stigma and discrimination in the workplace. Future studies must aim to develop culturally validated assessment tools and more research to understand the life course of the illness, in addition to systematically examining for more biological validators (animal models, genetics, imaging, neurotransmitters).

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic validity of premenstrual dysphoric disorder: revisited

Naik,

Nidhi,

Kumar

et al. 2023

Front. Glob. Womens Health

View full text Add to dashboard Cite

show abstract

“…However, this risk can be effectively reduced by concomitant use of progesterone ( 106 ). Therefore, a more effective and safer approach would be the use of combination preparations, such as the OC and COC preparations cited earlier ( 107 ).…”

Section: Hormone Treatmentmentioning

confidence: 99%

Premenstrual syndrome: new insights into etiology and review of treatment methods

Modzelewski,

Oracz,

Żukow

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

Premenstrual syndrome (PMS) is a common disorder affecting women of reproductive age, with an estimated global prevalence of 47.8%, with severe symptoms occurring in 3-8%, significantly affecting daily functioning. GABA conductance and changes in neurosteroid levels, particularly allopregnanolone, are suspected to play a substantial role in the disorder’s etiology. In this paper, we provide an overview of recent reports on the etiology and recognized therapeutic approaches, encompassing both pharmacological and non-pharmacological interventions. Our examination includes studies on SSRIs, hormonal agents, neurosteroids, supplementation, and therapeutic roles. We aim to determine the most favorable treatment regimen by comparing medication effects and alternative methods. The treatment of PMS is crucial for enhancing the quality of life for affected women. Medications used in PMS treatment should be individually selected to achieve the best therapeutic effect, considering the clinical situation of the patients.

show abstract

“…La eficacia de los abordajes quirúrgicos mencionados en esta sección no está del todo clara. Se requiere mayor evidencia para recomendarlos formalmente como alternativas terapéuticas en casos refractarios (Carlini et al, 2022).…”

Section: Cirugíaunclassified

Avances en el manejo del Trastorno Disfórico Premenstrual

Guzmán Castellanos,

Zamanillo Tanús,

Medina Barragán

et al. 2023

AEBMedicine

View full text Add to dashboard Cite

El Trastorno Disfórico Premenstrual (TDPM) incluye una constelación de síntomas físicos, cognitivos y/o afectivos que aparecen en la fase luteínica del ciclo menstrual y remite con la menstruación. Las etiología se desconoce en su mayoría pero las teorías más aceptadas se relacionan con la respuesta alterada del eje hipotálamo-hipófisis-gónadas, la hiposensibilidad de los receptores GABA-a a alopregnanolona y el desequilibrio en la serotonina, sistema inmune, calcio y del ciclo circadiano. Las manifestaciones son lo suficientemente severas para interferir con las actividades de la vida diaria. El tratamiento de primera línea incluye a los cambios en el estilo de vida, inhibidores selectivos de la recaptación de serotonina (ISRS), anticonceptivos hormonales combinados y las benzodiacepinas. Esta revisión narrativa de la literatura expone las terapias complementarias no farmacológicas con mayor evidencia cómo el ejercicio, la terapia cognitivo conductual, la suplementación de vitaminas y minerales, las técnicas de relajación, los fitofármacos, ademásde las terapias farmacológicas más novedosas.

show abstract

Management of Premenstrual Dysphoric Disorder: A Scoping Review

Cited by 22 publications

References 183 publications

Diagnostic validity of premenstrual dysphoric disorder: revisited

Diagnostic validity of premenstrual dysphoric disorder: revisited

Premenstrual syndrome: new insights into etiology and review of treatment methods

Avances en el manejo del Trastorno Disfórico Premenstrual

Contact Info

Product

Resources

About